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Pargeted Inhibition of -Adrenergic
eceptor Kinase-1–Associated Phosphoinositide-3
inase Activity Preserves -Adrenergic
eceptor Signaling and Prolongs Survival in
eart Failure Induced by Calsequestrin Overexpression
inzia Perrino, MD,* Sathyamangla V. Naga Prasad, PHD,* Mrinali Patel*, Matthew J. Wolf, MD, PHD,*
oward A. Rockman, MD*†
urham, North Carolina
OBJECTIVES Desensitization and down-regulation of -adrenergic receptors (ARs) are prominent features of
heart failure largely mediated by increased levels of AR kinase-1 (ARK1).
BACKGROUND -adrenergic receptor kinase 1 interacts with phosphoinositide-3 kinase (PI3K), and upon
agonist stimulation, the ARK1/PI3K complex is recruited to agonist-stimulated ARs.
Here we tested the hypothesis that in vivo selective inhibition of ARK1-associated PI3K
activity would preserve AR signaling and, therefore, improve cardiac function and survival
in experimental heart failure.
METHODS We used a murine model of heart failure induced by calsequestrin (CSQ) cardiac-specific
overexpression; CSQ mice were crossed with mice overexpressing in the heart a catalytically
inactive PI3K (PI3Kinact) to competitively displace endogenous PI3K from ARK1.
RESULTS Catalytically inactive PI3KPI3K overexpression in CSQ mice inhibited ARK1-associated
PI3K activity, normalized AR levels, and preserved AR responsiveness to isoproterenol
(ISO). Restoration of AR signaling via PI3Kinact overexpression resulted in marked
improvement of cardiac function and a significant prolongation of survival. Importantly, the
effects of PI3Kinact overexpression were restricted to AR signaling, because cellular PI3K
signaling was unaltered, as shown by the similar activation of multiple downstream signaling
pathways in both CSQ and CSQ/PI3Kinact mice.
CONCLUSIONS These data in the CSQ model of cardiac dysfunction indicate that membrane-targeted PI3K
activity plays a detrimental role in heart failure, and its inhibition represents a novel
therapeutic approach to ameliorate cardiac dysfunction and improve survival. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.062Cardiol 2005;45:1862–70) © 2005 by the American College of Cardiology Foundation
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reart failure is a complex disorder whose prognosis remains
oor, despite continuous advances in therapy (1). Clarification
f the signaling pathways that promote deterioration of cardiac
unction is an intense area of research because inhibition of
hese deleterious signals could serve as a novel therapeutic
pproach.
Failing human hearts are characterized by extensive
bnormalities of the -adrenergic receptor (AR) system,
ncluding down-regulation and desensitization of ARs
esulting in a state of reduced responsiveness to agonist
timulation (2). Interestingly, whether changes in AR
ignaling represent an adaptive and protective process, as
ome postulate (3), or whether AR dysregulation is actu-
lly detrimental (4) is still controversial. Results from our
revious studies suggest that chronic AR dysfunction in
he failing heart is maladaptive and contributes to the
eterioration in cardiac function (5–7).
Previous studies have shown that agonist-induced AR
ysfunction begins with receptor phosphorylation, followed
From the Departments of *Medicine, †Cell Biology and Molecular Genetics, Duke
niversity Medical Center, Durham, North Carolina. This work was supported by a
ational Institutes of Health grant to Dr. Rockman (HL-61558).r
Manuscript received December 13, 2004; revised manuscript received January 28,
005, accepted February 14, 2005.y rapid uncoupling of the receptor from its cognate G
rotein (desensitization), and subsequent targeting of the
hosphorylated receptor for endocytosis, a process linked to
hronic receptor down-regulation (4). Phosphorylation can
e mediated by second messenger kinases (for example
rotein kinase A or protein kinase C), or by a specialized
amily of G protein-coupled receptor kinases (GRKs) (7,8);
RK2, known commonly as AR kinase-1 (ARK1), is
he most abundant isoform expressed in the heart (9,10).
ecause ARK1 levels are consistently and markedly ele-
ated in both human (11) and experimental heart failure
5,7,12), up-regulation of ARK1 has been postulated to
lay an important role in the reduced AR responsiveness
ssociated with cardiac dysfunction.
Upon agonist stimulation, binding of cytosolic ARK1 to
iberated G subunits facilitates its translocation to the plasma
embrane, resulting in the phosphorylation of agonist-
ccupied receptors (13). We have recently demonstrated
hat ARK1 forms a cytosolic complex with phosphoino-
itide-3 kinase (PI3K) (14). Upon agonist stimulation, the
ARK1/PI3K complex is recruited to activated ARs (15),
herein generation of D-3 phosphoinositides by PI3K is
equired for receptor endocytosis (14). In vivo, inhibition of
eceptor-localized PI3K activity prevents AR abnormalities
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n less deterioration in cardiac function (7). However, whether
argeted inhibition of PI3K can rescue AR abnormalities
nder conditions of chronic heart failure, and ultimately
mprove cardiac function and survival, is not known. To test
his, we used a murine model of heart failure induced by
ardiac-specific overexpression of the calcium-binding protein
alsequestrin (CSQ) (16). This model recapitulates human
eart failure in many aspects, including the morphological
rogression from cardiac hypertrophy to dilated cardiomyop-
thy (16), the high rate of premature death (6), and the
ensitivity to beta-blocker therapy (6).
In order to inhibit AR-localized PI3K activity in failing
earts, we bred the CSQ mice with transgenic mice overex-
ressing a catalytically inactive PI3K (PI3Kinact) that com-
etitively displaces the endogenous enzyme from ARK1,
herefore preventing its recruitment to agonist-stimulated
ARs. We determined the effects of PI3Kinact overexpression
n AR function and PI3K signaling, and monitored the
rogression of cardiac dysfunction and the rates of survival of
ingle and binary transgenic mice.
ETHODS
xperimental animals. Mice overexpressing CSQ or
I3Kinact were engineered as previously described (7,16).
riefly, the alpha-myosin heavy chain promoter was used to
rive cardiac-targeted overexpression of canine cardiac CSQ
r a PI3K mutant lacking the adenosine triphosphate-
inding domain (PI3Kinact). To ensure identical genetic
ackgrounds, both CSQ and PI3Kinact strains were back-
rossed 10 generations onto a dilute brown non-agouti
enetic background. F1 pups were generated from the
rossbreeding of CSQ transgenic mice with PI3Kinact
ransgenic mice. Wild type (WT), CSQ transgenic, or
SQ/PI3Kinact transgenic littermates of either gender
ere used for this study and were handled according to the
pproved protocols and the animal welfare regulations at
uke University Medical Center.
embrane fractionation, AR radioligand binding, and
denylyl cyclase activity. Membrane and cytosolic frac-
Abbreviations and Acronyms
AR  -adrenergic receptor
ARK1  AR kinase-1
cAMP  cyclic adenosine monophosphate
CSQ  calsequestrin
GSK  glycogen synthase kinase 3
ISO  isoproterenol
MAPKs  mitogen-activated protein kinases
PKB  protein kinase B
PI3K  phosphoinositide-3 kinase
PI3Kinact catalytically inactive PI3K
WT  wild type
%FS  percent fractional shorteningions from left ventricles flash-frozen in liquid N2 were prepared as described previously (8). Because we have
reviously shown the Kd of
125I-CYP binding to the ARs
n membranes prepared from mouse hearts is 30 pmol/l
17), we used a single saturating concentration of 125I-CYP
250 pmol/l) to assess the total AR density in the mouse
ardiac membranes. Receptor density (fmol) was normalized
o milligrams of membrane protein. Adenylyl cyclase assays
ere performed as described previously (8), using 20 g of
he membrane fraction. Generated cyclic adenosine mono-
hosphate (cAMP) was quantified using a liquid scintilla-
ion counter (MINAXI-4000, Packard Instrument Co.,
erkinElmer, Boston, Massachusetts).
mmunoprecipitation and immunoblotting. Immuno-
recipitation and immunoblotting were performed as de-
cribed previously (7,8). Detection was carried out using
CL (Amersham Biosciences Corp., Piscataway, New Jer-
ey), and bands were quantified using Bio-Rad (Hercules,
alifornia) Flouro-S Multimage software densitometry.
I3K. Phosphoinositide 3-kinase activity assays were car-
ied out by immunoprecipitation of the PI3K and 
soforms from the cytosolic fraction as described previously
15). ARK1-associated PI3K activity was measured after
mmunoprecipitation of 400 g of proteins from the mem-
rane fraction with polyclonal antibody directed against
ARK1 (Santa Cruz Biotechnology Inc., Santa Cruz,
alifornia).
itogen-activated protein kinase activity. Mitogen-
ctivated protein kinase activities were assessed from left
entricular cytosolic extracts as the capacity of immuno-
recipitated extracellular signal-regulated kinase (ERK)2-
42/ERK1-p44, c-Jun N-terminal kinase (JNK)1, p38, and
38-beta (Santa Cruz) to phosphorylate in vitro substrates
myelin basic protein and glutathione S transferase [GST]-
roto-oncogene c-Jun [cJun]) as previously described (18).
NA isolation and Northern blotting. RNA was isolated
rom left ventricles using the RNA-Bee-RNA isolation
eagent (Tel-Test Temco Inc., Friendswood, Texas) ac-
ording to the manufacturer’s instructions; 10 g of RNA
ere size-fractionated by denaturing formaldehyde gel elec-
rophoresis, transferred to nylon membrane by capillary
ction, cross-linked with ultraviolet light, and hybridized
ith a mouse 1AR
32P-labeled cDNA probe. After hy-
ridization, filters were washed under stringent conditions,
nd transcripts were detected by autoradiography.
ransthoracic echocardiography. Serial echocardiography
as performed on conscious mice with an HDI 5000
chocardiograph (Philips, Böblingen, Germany) at 8, 12,
nd 16 weeks of age, as previously described (19).
tatistical analysis. Data are expressed as mean values 
EM. Multigroup comparisons were performed using one-
ay analysis of variance (ANOVA) with Neuman-Keuls
orrection. Serial echocardiography results were analyzed
y repeated-measures ANOVA. Survival was analyzed by
aplan-Meier analysis. Hazard ratios for the presence of
I3Kinact transgene and gender were derived from the Cox
roportional hazard model using SAS software (SAS Insti-
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Targeted Inhibition of PI3K in Heart Failure June 7, 2005:1862–70ute, Cary, North Carolina). For all analyses, p  0.05 was
onsidered significant.
ESULTS
ompetitive displacement of endogenous PI3K from
ARK1 preserves AR signaling in heart failure. To
est the hypothesis that cardiac inhibition of receptor-
argeted PI3K activity would ameliorate AR signaling
nd, in turn, alter the progression of heart failure, we
ompared the molecular phenotype of single CSQ trans-
enic mice and binary CSQ/PI3Kinact mice (7). In order
o assess receptor-localized PI3K activity in failing
earts, ARK1 was immunoprecipitated and assayed for
ssociated PI3K activity in the cardiac membranes of
2-week-old mice; CSQ hearts displayed a marked in-
rease of ARK1-associated PI3K activity compared
ith WT controls (Fig. 1A, 2.4  0.8-fold induction in
igure 1. Catalytically inactive phosphoinositide-3 kinase  (PI3Kinact)
verexpression normalizes AR kinase-1 (ARK1)-associated PI3K activ-
ty in failing hearts from calsequestrin (CSQ) transgenic mice. (a) ARK1-
ssociated PI3K activity in cardiac membranes from wild type (WT) (n 
), CSQ (n  8), and CSQ/PI3Kinact (n  8) mouse hearts. *p  0.001
SQ vs. WT or CSQ/PI3Kinact (analysis of variance with Neuman-Keuls
orrection); PI3K (b) or  (c) activities were assayed from the cytosolic
xtracts of the same hearts. Left panels show representative PI3K assays;
ight panels show summary data. There was no significant increase in the
ctivity of PI3K over WT levels in both CSQ or CSQ/PI3Kinact (in
SQ 1.0  0.3-fold, in CSQ/PI3Kinact 0.7  0.1-fold compared with
T). Ori  origin; PIP  phosphatidylinositol-mono-phosphate; PIP2
phosphatidylinositol-bis-phosphate.SQ over WT, *p  0.001 CSQ vs. WT, ANOVA with aeuman-Keuls correction), consistent with our previous
tudies showing increased ARK1 levels (7,20). Impor-
antly, PI3Kinact overexpression completely displaced
ndogenous PI3K from ARK1, reducing ARK1–
ssociated PI3K activity in CSQ/PI3Kinact mice to
ontrol levels (Fig. 1A, *p  0.001 CSQ vs. CSQ/
I3Kinact). Because PI3K and PI3K are known to
lay important roles in cardiac growth and function
7,21,22) and to interact with ARK1 (7), we sought to
etermine the relative activities of the PI3K isoforms
nder conditions of heart failure. PI3K and PI3K were
mmunoprecipitated from the cytosolic fraction of the
ame hearts and assayed for PI3K activity. Compared
ith WT controls, failing CSQ hearts were characterized
y a selective significant increase in the activity of PI3K
Fig. 1B, *p  0.001 CSQ vs. WT), which was markedly
educed by the overexpression of the PI3Kinact transgene
in CSQ/PI3Kinact 0.6  0.2-fold compared with WT,
p  0.001 CSQ vs. CSQ/PI3Kinact, ANOVA with
euman-Keuls correction). In contrast, no significant
hanges in PI3K activity were detected among the differ-
nt groups (Fig. 1C).
We next tested whether targeted inhibition of PI3K
ctivity within the receptor complex would correct ab-
ormalities in AR signaling in CSQ mice by directly
easuring AR density and adenylyl cyclase activity in
embrane fractions from WT, CSQ, and CSQ/
I3Kinact hearts; CSQ overexpressing hearts were char-
cterized by a significant 25% reduction in AR density
nd depressed isoproterenol (ISO)-stimulated cyclase
ctivity (Table 1). Interestingly, inhibition of ARK1–
ssociated PI3K activity in CSQ/PI3Kinact mice com-
letely normalized AR density to WT levels (Table 1)
ithout having any effect on the transcriptional regula-
ion of ARs (Fig. 2A). Increased AR levels in CSQ/
I3Kinact mice were also accompanied by a significant
mprovement in AR responsiveness to agonist, as mea-
ured by enhanced response in membrane adenylyl cyclase
ctivity and increased cAMP generation (Table 1); ISO-
timulated adenylyl cyclase activity exhibited a nonsignif-
cant lower trend in CSQ/PI3Kinact-overexpressing
ice compared to WT, despite the complete normaliza-
ion of AR density. These results are likely attributed to
he persistent increase in the membrane levels of protein
inhibitory (Gi) in both single CSQ and binary CSQ/
I3Kinact transgenic hearts (data not shown).
argeted inhibition of PI3K at the site of activated ARs
oes not affect downstream PI3K cellular signaling. Be-
ause PI3K plays an important role in regulating cellular
ignaling, we wanted to exclude the possibility that overex-
ression of PI3Kinact altered the activity of downstream
inases such as the mitogen-activated protein kinases
MAPKs), protein kinase B (PKB), and glycogen synthase
inase 3 (GSK) in transgenic hearts. Compared with WT,
e found a significant increase in the activity of all MAPKsnalyzed (ERK, JNK, and p38/p38) in CSQ mouse hearts
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ice did not affect the activity of any of the three major
APKs pathways (Figs. 2B to 2E), and, importantly, it did
Table 1. AR Signaling in WT, CSQ, and CS
AR Density
fmol/mg
protein
(n  16)
WT 35.1  2.0
CSQ 26.2  1.7*
CSQ/PI3Kinact 36.35  3.25
*p  0.05 CSQ vs. WT or CSQ/PI3Kinact; †p  0.05 WT,
with Neuman-Keuls correction); sodium fluoride-induced
CSQ/PI3Kinact  183.7  10.8 (pmol/mg/min).
AR  -adrenergic receptor; cAMP  cyclic adenosine
inactive phosphoinositide 3-kinase; WT  wild type.
igure 2. Inhibition of receptor-localized phosphoinositide 3-kinase (PI3K) ac
howing -adrenergic receptor (1AR) levels in 12-week-old wild type (WT), c
upper panel); equal loading of the different RNA samples was confirm
itogen-activated protein kinase activation was determined in WT, CSQ, a
rotein (MBP) or recombinant glutathione S transferase-proto-oncogene c-Ju
t least six independent experiments are shown for extracellular signal-related ki
lotting was carried out to evaluate total protein levels of each kinase (b to
euman-Keuls correction). (f) Western blotting analysis showing similar activation
onditions in single CSQ and binary CSQ/PI3Kinact mice. IB  immunoblottingot change the phosphorylation status of PKB or of GSK,
nown downstream targets of PI3K (Fig. 2F). Taken
ogether, these studies show that overexpression of
I3Kinact Mice
Adenylyl Cyclase Activity pmol/mg
Protein/min of cAMP
(n  12)
Basal Iso 104 M
36.2  1.3 55.6  2.5†
27.6  2.1 36.4  1.7*†
30.6  2.0 43.8  2.0†
, or CSQ/PI3Kinact vs. respective basal (analysis of variance
generation: WT  219.8  13.1; CSQ  156.6  8.5;
hosphate; CSQ  calsequestrin; PI3Kinact  catalytically
does not affect downstream signaling pathways. (a) Northern blotting analysis
estrin (CSQ), and CSQ/catalytically inactive PI3K (CSQ/PI3Kinact) hearts
methylene blue staining of nylon membranes (bottom panel). (b to e)
Q/PI3Kinact hearts by the ability to in vitro phosphorylate myelin binding
T-cJun). Representative kinase assays and relative densitometric evaluation of
ERK) (b), c-Jun N-terminal kinase (JNK) (c), p38 (d), and p38 (e). Western
 0.01 for CSQ or CSQ/PI3Kinact versus WT (analysis of variance withQ/P
CSQ
cAMPtivity
alsequ
ed by
nd CS
n (GS
nase (
d). *pof protein kinase B (PKB) and glycogen synthase kinase (GSK) under basal
; IP  immunoprecipitation.
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Targeted Inhibition of PI3K in Heart Failure June 7, 2005:1862–70I3Kinact primarily functions to competitively displace
ndogenous PI3K from ARK1, thereby normalizing AR
ignaling in failing hearts without altering other known
I3K downstream pathways.
reservation of AR signaling by targeted inhibition of
I3K improves cardiac function and delays the progres-
ion of cardiomyopathy in CSQ transgenic mice. To
valuate the effects of improved AR signaling on the
rogression of cardiac dysfunction due to CSQ overexpres-
ion, serial echocardiography was performed on both groups
f heart failure mice (CSQ and CSQ/PI3Kinact) at 8, 12,
nd 16 weeks of age and on WT mice (Table 2, Fig. 3);
SQ hearts underwent a progressive enlargement of the left
entricle and deterioration of cardiac function over time,
xpressed by reduced fractional shortening (%FS) (Table 2,
ig. 3). Calsequestrin/PI3Kinact mice showed a smaller left
entricular end-diastolic diameter compared with age-
atched CSQ mice (Fig. 3B, left panel), but exhibited a
imilar rate of enlargement of the left ventricular end-
iastolic diameter over time (Fig. 3B, right panel). In
ontrast, PI3Kinact overexpression in CSQ mice not only
educed left ventricular end-systolic diameter, but it also
ignificantly reduced the rate of left ventricular end-systolic
iameter enlargement over time in CSQ/PI3Kinact mice
Fig. 3C, left and right panels). At all time points, CSQ/
I3Kinact mice had significantly improved %FS compared
o CSQ mice (Fig. 3D, left panel), and, importantly,
SQ/PI3Kinact mice had a slower progression of cardiac
ysfunction over time (Fig. 3D, right panel). The echocar-
iographic results for cardiac size were independently con-
rmed in another set of animals that underwent dissection
nd measurement of left ventricular weight, heart weight,
nd body weigh at 12 weeks of age (Fig. 4). Overexpression
f the CSQ transgene markedly increased left ventricular
eight/body weight and heart weight/body weight ratios
ompared with WT levels (Fig. 4, *p  0.0001 WT vs.
SQ or CSQ/PI3Kinact, ANOVA with Neuman-Keuls
orrection). Importantly, PI3Kinact overexpression in CSQ
ice significantly reduced left atrial weight as well as left
able 2. Echocardiographic Measurements in WT, CSQ, and CS
WT (12 Weeks)
(n  20)
8 Weeks
CSQ
(n  16)
CSQ/PI3K
(n  17
erial echocardiography
LVEDD, mm 2.8  0.1* 4.1  0.1 3.8  0.1
LVESD, mm 1.0  0.1* 2.6  0.1 1.9  0.1
IVS, mm 0.9  0.1 0.9  0.1 1.0  0.1
PW, mm 0.8  0.1 0.9  0.1 0.9  0.1
FS, % 64.5  1.1* 37.5  2.3 47.2  2.1
Mean Vcfc, circ/s 4.8  1.4* 2.8  0.2 3.5  0.1
Heart rate, beats/min 648  6.3* 545  9.4 551  11
p  0.0001 WT vs. CSQ or CSQ/PI3Kinact at all time points; †p  0.05 CSQ or
SQ (repeated measures ANOVA).
FS  fractional shortening; IVS  interventricular septum; LVEDD  left ventri
cfc  ventricular circumferential shortening, corrected by heart rate. Other abbrevQ/PI3Kinact Mice
12 Weeks 16 Weeks
inact
)
CSQ
(n  15)
CSQ/PI3Kinact
(n  16)
CSQ
(n  13)
CSQ/PI3Kinact
(n  15)
4.7  0.1† 4.2  0.1‡ 5.1  0.2† 4.7  0.1†‡
‡ 3.3  0.2† 2.4  0.2†‡ 4.2  0.2† 3.2  0.2†‡
0.9  0.1 0.9  0.1 0.8  0.1 0.9  0.1
0.8  0.1 0.9  0.1 0.7  0.1 0.8  0.1
‡ 29.9  2.6† 42.7  2.9‡ 18.2  1.7† 31.1  2.9†‡
‡ 2.2  0.2† 3.4  0.4‡ 1.3  0.1† 2.3  0.2†‡
.0‡ 563  14.2† 499  30.1‡ 482  20.4† 524  24.2†‡
CSQ/PI3Kinact vs. respective 8-week value; ‡p  0.01 CSQ/PI3Kinact vs. age-matchedentricular weight/body weight and heart weight/body
y
tigure 3. Cardiac specific overexpression of catalytically inactive
hosphoinositide-3 kinase  (PI3Kinact) improves cardiac function of
alsequestrin (CSQ) transgenic mice. (a) Representative echocardio-
rams from CSQ or CSQ/PI3Kinact mice at 8, 12, and 16 weeks of age.
bsolute values of left ventricular end-diastolic diameter (LVEDD, b),
eft ventricular end-systolic diameter (LVESD, c), and % fractional
hortening (%FS, d) in age-matched wild type (WT) (striped circle),
SQ (solid circle), and CSQ/PI3Kinact (open circle) mice are shown
n the left panels. In the right panels percent change variation over
ime is also shown for CSQ and CSQ/PI3Kinact mice. *p  0.05 CSQ
r CSQ/PI3Kinact vs. respective eight weeks measurement; †p  0.05
SQ/PI3Kinact vs. CSQ age-matched mice (repeated measures anal-sis of variance); ‡p  0.0001 WT vs. CSQ or CSQ/PI3Kinact at all
ime points.
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.01 CSQ/PI3Kinact vs. CSQ).
elective inhibition of AR-targeted PI3K activity pro-
ongs survival of heart failure in CSQ transgenic
ice. To test whether PI3Kinact-mediated improvement
n cardiac function would translate to a benefit on lifespan,
urvival analysis was conducted in CSQ mice, binary trans-
enic CSQ/PI3Kinact mice, and their WT littermates. As
xpected, cardiac overexpression of the CSQ gene resulted
n premature death (Fig. 5A). However, PI3Kinact overex-
ression markedly prolonged the lifespan of CSQ mice as
hown by Kaplan-Meier analysis (Fig. 5A). Remarkably,
nhibition of AR-targeted PI3K activity completely inhib-
ted death events in CSQ mice of both genders within the
rst five months of life (Cox proportional hazard analysis
ensored at 150 days of survival: *p  0.05 for PI3Kinact; p
0.3 for gender). Interestingly, this beneficial effect was
aintained for a longer period of time in CSQ/PI3Kinact
ice of female gender (Fig. 5B, Cox proportional hazard
nalysis: †p  0.01 for PI3Kinact and female gender).
The gender-related difference in survival is likely not
ttributed to a greater effect of the transgene in female
ice, because PI3Kinact overexpression resulted at 12
eeks of age in similar improvements for both genders in
AR signaling (AR density, fmol/mg of protein: CSQ/
I3Kinact males  38.6  1.2; CSQ/PI3Kinact females
31.1  2.65), ISO-stimulated adenylyl cyclase activity
pmol of cAMP/mg/min: CSQ/PI3Kinact males  42.8
3.1; CSQ/PI3Kinact females  45.4  3.9), and
ardiac function (%FS: CSQ/PI3Kinact males  48.3 
.4; CSQ/PI3Kinact females  44.9  1.1). Moreover,
o differences in the expression levels of the two trans-
enes were observed between males and females in either
igure 4. Targeted inhibition of phosphoinositide-3 kinase (PI3K) reduces
ardiac chamber size. Bar graphs showing (a) body weight (BW), (b) left
trium (LA) weight, (c) left ventricular weight/body weight (LV/BW), (d)
eart weight/body weight (H/BW) in wild type (WT) mice, single
alsequestrin (CSQ) transgenic, and binary CSQ/catalytically inactive
hosphoinositide 3-kinase  (PI3Kinact) transgenic mice. *p  0.0001
T vs. CSQ or CSQ/PI3Kinact; †p  0.01 CSQ/PI3Kinact vs. CSQ
analysis of variance with Neuman-Keuls correction).oung (12-week-old) or older mice (age 160 to 252 days),
d
andicating that the survival advantage of female CSQ/
I3Kinact mice is not related to differential regulation of
he transgenes according to gender or age (Fig. 6).
ISCUSSION
n the present study, we report that targeted inhibition of
ARK1-associated PI3K activity preserves AR signaling
nd improves cardiac function and survival in the murine
odel of severe heart failure induced by CSQ overexpres-
ion. Importantly, the effects of targeted inhibition of PI3K
ctivity are specific to AR signaling because MAPKs and
ther PI3K downstream pathways are unaffected. Our
ndings in this genetic model of heart failure are consistent
ith our previous reports in the mouse models of chronic
atecholamine stimulation and pressure overload (7), sug-
esting that receptor-targeted inhibition of PI3K activity
ight represent a novel therapeutic approach in the treat-
ent of the failing heart.
igure 5. Restoration of -adrenergic receptor function improves survival
n mice with heart failure. (a) Kaplan-Meier survival curves of wild type
WT) (n  18), calsequestrin (CSQ) (n  19), and CSQ/catalytically
nactive phosphoinositide 3-kinase  (PI3Kinact) (n  20) mice; CSQ
ice had a mean survival age of days 151.9  18.6, whereas CSQ/
I3Kinact mice reached a mean survival age of 234.2  14.3 days. *p 
.001 for WT vs. CSQ or CSQ/PI3Kinact; †p  0.001 CSQ/PI3Kinact
s. CSQ, Kaplan-Meier analysis. (b) Kaplan-Meier survival curves accord-
ng to gender in CSQ (females, n 11; males, n 8) and CSQ/PI3Kinact
ice (females, n  11; males, n  9). In the analysis censored at 150 days,
p 0.05 for PI3Kinact, p 0.3 for gender; in the analysis censored at 300
ays, †p 0.01 for PI3Kinact and female gender (Cox proportional hazard
nalysis).
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Targeted Inhibition of PI3K in Heart Failure June 7, 2005:1862–70-adrenergic receptors are the most important regulators
f cardiac function in vivo by interacting with endogenous
atecholamines epinephrine and norepinephrine. In the
ailing human heart, increased levels of circulating cat-
cholamines are associated with a reduction of cardiac AR
ensity and desensitization of the remaining receptors
2,23). Our study shows that translocation of PI3K to
ctivated receptors is an important step in the series of
vents that ultimately lead to chronic receptor down-
egulation in heart failure. Moreover, similar to previous
bservations in different animal models, our data shows that
trategies that restore AR signaling consistently ameliorate
ardiac dysfunction and improve survival in heart failure
5–7,12). Our data are also consistent with clinical studies
howing that the treatment of patients with heart failure
ith beta-blockers actually results in the restoration of AR
unction, thereby improving cardiac function as well as
urvival (24–27).
In addition to highlighting the important role of AR-
ocalized PI3K activity in failing hearts, our data also
uggest that preferential activation of PI3K isoform might
igure 6. Equal expression levels of calsequestrin (CSQ) and catalytically
ale and female mice. Representative immunoblottings (two animals/grou
howing similar expression levels of the alpha-myosin-heavy-chain-driven
nd male mice at 12 weeks of age (a, 84 days, 12 weeks) or older (b, 160
ARK1) in the cytoplasm of the same animals were also unchanged.lay a role in the pathogenesis of heart failure. A number of secent studies have demonstrated an important role for
I3K in the regulation of cardiac function (7,15,22,28,29).
ecently, it has been shown that PI3K can regulate
ntracellular cAMP levels after pressure overload by inter-
cting with the phosphodiesterase PDE3B (29). This inter-
ction, likely based on the formation of a large multiprotein
omplex, does not require the kinase activity of PI3K
ecause it was preserved in mice with a “knock-in” of a
I3K kinase-dead mutant gene (29). These interesting
bservations suggest that the regulation of intracellular
AMP levels is a complex process that results from a balance
etween cAMP generating and degradating pathways (29).
lthough it is not known whether the knock-in of the
inase-dead PI3K would actually normalize AR levels
nd function (29), our data from this study would predict
hat the kinase-dead PI3K would displace the active PI3K
nzyme from ARK1 and lead to the normalization of AR
ignaling under pathological conditions. In fact,
large body of data using different in vitro and in vivo
pproaches, including the present study, indicates that
nhibition of AR-targeted kinase activity of PI3K pre-
ve phosphoinositide 3-kinase  (PI3Kinact) transgenes in young and old
relative quantitative densitometric analysis (three to four animals/group)
genes CSQ and PI3Kinact in the cytosolic fraction of hearts from female
2 days, 22 weeks). Expression levels of -adrenergic receptor kinase 1inacti
p) and
transerves AR function under pathological conditions
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June 7, 2005:1862–70 Targeted Inhibition of PI3K in Heart Failure7,14,15,28). Distinctively, unlike strategies that uti-
ize chronic AR activation as a therapy, such as chronic
atecholamine infusion, overexpression of ARs or Gs
30–33), our approach of displacing the kinase activity of
I3K from ARK1 selectively restores agonist-dependent
AR signaling without inducing chronic AR stimulation,
process we believe inherently maladaptive (4). Moreover,
vidence is accumulating to support the concept that inter-
alization of ARs per se is pathological, because the
nternalizing receptor can directly activate maladaptive sig-
aling pathways in a G-protein–independent fashion (34).
herefore, inhibition of AR down-regulation might actu-
lly prevent the activation of pathological pathways because
t blocks maladaptive signals triggered by AR internaliza-
ion (34).
Importantly, we have previously shown that the absence
f PI3K is not sufficient to prevent the increase in
ARK1-associated PI3K activity on chronic catecholamine
timulation, because other isoforms of PI3K can eventually
nteract with ARK1 through the conserved phosphoino-
itide-kinase domain of PI3K and be targeted to activated
eceptors (7). Indeed, it has been recently shown that PI3K
nockout mice undergo deterioration of cardiac function
ith necrosis and fibrosis when exposed to pressure overload
29). Therefore, a successful therapeutic strategy would
equire the displacement of all PI3K isoforms from ARK1,
ather than the inhibition of a single isoform. Because the
egion responsible for the interaction with ARK1 is
ommon to all PI3K isoforms, this therapeutic aim could be
ccomplished by the overexpression of small molecules that
imic this region and competitively displace the endoge-
ous enzymes from the complex with ARK1.
Undoubtedly, the most appealing aspect of this novel
trategy is its specificity for AR-associated PI3K signaling;
I3Kinact overexpression in transgenic mice reduces the
mount of active PI3K enzyme targeted to agonist-
timulated receptors but, importantly, does not affect other
I3K cytosolic downstream-signaling pathways. Indeed, in
ontrast to other PI3K mutants (29), PI3Kinact overex-
ression does not alter PKB/GSK and MAPKs pathways,
or does it affect basal cAMP levels. Although it is
onceivable that overexpression of PI3Kinact might interact
n the cytosol with phosphodiesterases (29) or directly affect
denylyl cyclase (7,21,22), we believe it is unlikely because
nly agonist-stimulated, and not basal cyclase activity, is
ffected in the binary CSQ/PI3Kinact, which indicates the
estoration of normal AR-Gs coupling.
In contrast to the overexpression of the C-terminus of
ARK1, which we have shown to ameliorate cardiac dys-
unction in a number of heart failure models by disrupting
he ARK1/G- interaction (5,6,12), selective inhibition
f receptor-localized PI3K activity does not interfere with
--mediated translocation of ARK1 to the receptor
omplex, or with other G--mediated signals. Interest-
ngly, because PI3Kinact preserves AR responsiveness to
atecholamine stimulation without inhibiting receptorhosphorylation by ARK1, these results suggest that
I3Kinact overexpression might possibly preserve AR
ignaling by promoting a rapid sequence of receptor dephos-
horylation and recycling to the plasma membrane.
An additional unanticipated finding in our study was that
he PI3Kinact-mediated preservation of AR signaling
esulted in a prolonged beneficial effect on survival in female
ice. This result is congruent with data from clinical trials
ith heart failure patients indicating the existence of gender-
elated differences in heart failure for presentation, etiology,
nd long-term survival (35,36). Moreover, our results are
onsistent with previous data from experimental studies
howing reduced susceptibility of female mice to ischemia/
eperfusion injury (37,38), confirming the presence of a
ender-related advantage for females in response to cardio-
ascular injury. These results are likely to depend on
ormonal differences between genders, and future studies
ill be needed to specifically address the role of estrogens/
ndrogens in this murine model of heart failure.
In conclusion, our study demonstrates that membrane-
argeting of PI3K at the site of activated ARs exerts an
mportant role in the processes that lead to AR down-
egulation. Competitive displacement of PI3K from
ARK1 preserves AR signaling in the failing heart,
elaying the progression of cardiac dysfunction and pro-
onging the lifespan in this murine model of genetic heart
ailure. Hence, inhibition of AR-localized PI3K activity
epresents a novel therapeutic approach for patients with
eart failure.
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